Gastric Cancer Treatment Market
Global Gastric Cancer Treatment Market Size, Share & Trends Analysis Report by Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy), and by End-User (Hospitals and Clinics, Specialized Cancer Treatment Centres, and Others) and Forecast 2019-2025
Gastric cancer treatment market is expected to grow with a CAGR of 4.9% during the forecast period. Gastric cancer is one of the most common cancers globally in which malignant cells form in the lining of the stomach. Bacterium Helicobacter pylori have been recognized as one of the primary reasons for the occurring of gastric cancer. Stomach cancer has a tendency to develop slowly over many years. Some of the early symptoms of gastric cancer include heartburn, indigestion, loss of appetite, and slight nausea, among more. The key factors contributing to the growth of the market include growing cases of gastrointestinal stromal tumors, lymphoma, carcinoid tumors, and lymphoma and the growing number of cancer treatment centers. In addition, innovations in treatment, increasing R&D activities, and combination therapy have also stimulated the growth of the gastric cancer treatment market.
Segmental Outlook
The market is segmented on the basis of therapy and end-user. Gastric cancer can be diagnosed using different test such as chest x-ray, computed tomography (CT or CAT) scan, helicobacter pylori, imaging tests, laparoscopy, magnetic resonance imaging (MRI) scan, positron emission tomography (PET) scan, and upper gastrointestinal (GI) series. Based on therapy, the market is segmented into adjuvant chemotherapy, chemotherapy, radiation therapy, surgery, and targeted drugs therapy. These therapies include various drug classes such as docetaxel, doxorubicin hydrochloride, fluorouracil, imatinib, mitomycin c, sunitinib, and trastuzumab. End-user segments include hospitals, clinics, specialized cancer treatment centers, and others.
Targeted Therapy Delivering Advanced Treatment
By therapy, the targeted drugs therapy segment is expected to record a relatively significant growth in the gastric cancer treatment market. Delivery of advanced techniques including enzyme therapy and stem cell therapy is the primary factor for growth in targeted therapy market. Targeted drug therapy tends to work in some cases where standard chemos fail to work. In such cases, trastuzumab, a targeted therapy drug, is given with chemotherapy.
Global Gastric Cancer Treatment Market by Therapy, 2018 (%)
Hospitals to Hold Significant Share among End-User
On the basis of end-user, the hospitals sub-segment is expected to grasp the larger share of the gastric cancer market. More and more hospitals are increasingly offering treatments for advanced stomach cancer, as well as diagnosis services as individuals are more secure than ever regarding concerning fatal diseases including gastric cancer. More individuals tend to consult gastroenterologist if they experience indigestion, heartburn, painful swallowing, bloated stomach, and frequent nausea, among other symptoms. Due to these factors, it is expected that more hospitals will provide treatment for gastric cancer.
Regional Outlook
The highest incidence and prevalence of stomach cancer has been predicted to be in Asia, Latin America and the Caribbean and the lowest incidence in North America and Africa. More than 60% of the global gastric cancer cases are from emerging economies such as South Korea, China, Japan, Mongolia, and India. Growing disposable income, awareness and healthcare spending will further drive the gastric cancer treatment market in the Asia-Pacific region. According to the statistics World Cancer Research Fund International of the year 2016, Japan have the largest market share with approximately 25% in the global stomach cancer treatment industry due to greater consumption of salty and pickled foods. Not only just Japan (31.1 new cases /100,000), other countries such as South Korea (41.4), China (29.9), and Mongolia (34) have high incidence rates of stomach cancer. Further, the market in North America and Europe is growing strongly in the uptake of gastric cancer drugs specifically Herceptin, Erbitux, and Afinitor, in particular.
Market Players Outlook
The key players in the global market include, F. Hoffmann-La Roche AG, Bristol-Myers Squibb, Co, Pfizer, Inc, Merck & Co., Inc, Celltrion, Inc., Abbott Laboratories, Inc., Bristol Myers Squibb, Co., Oncolytics Biotech Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Merck KGaA, Novartis AG and Otsuka Holdings Co. Ltd. Top companies are focusing on delivering differentiated treatments by adopting a new method of treatments through launched products and upcoming targeted therapies during the forecast period.
The Report Covers
- Market value data analysis of 2019 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global gastric cancer market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. F. Hoffmann-La Roche AG
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Bristol-Myers Squibb, Co.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Pfizer, Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Merck & Co., Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Celltrion, Inc.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Gastric Cancer Treatment Market by Therapy
5.1.1. Chemotherapy
5.1.2. Immunotherapy
5.1.3. Radiation Therapy
5.1.4. Targeted Therapy
5.1.5. Surgery
5.2. Global Gastric Cancer Treatment Market by End-User
5.2.1. Hospitals and Clinics
5.2.2. Specialized Cancer Treatment Centres
5.2.3. Others
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbott Laboratories, Inc.
7.2. Amgen, Inc.
7.3. ASLAN Pharmaceuticals Pte., Ltd.
7.4. AstraZeneca PLC
7.5. Athenex, Inc.
7.6. Bristol Myers Squibb, Co.
7.7. Celgene Corp.
7.8. Celltrion, Inc.
7.9. Eli Lilly and Co.
7.10. GlaxoSmithKline PLC
7.11. Hoffmann-La Roche AG
7.12. ImmunoGen, Inc.
7.13. Merck & Co., Inc.
7.14. Novartis AG
7.15. Oncolytics Biotech, Inc.
7.16. Otsuka Holdings Co., Ltd.
7.17. Pacific Edge, Ltd.
7.18. Pfizer, Inc.
7.19. Polaris Pharmaceuticals, Inc.
7.20. Thermo Fisher Scientific, Inc.
1. GLOBAL GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
2. GLOBAL CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
3. GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
4. GLOBAL RADIATION THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
5. GLOBAL TARGETED THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
6. GLOBAL SURGERY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
7. GLOBAL GASTRIC CANCER TREATMENT MARKET BY END-USER
8. GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
9. GLOBAL SPECIALIZED CANCER TREATMENT CENTRES MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
10. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
11. GLOBAL GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
12. NORTH AMERICAN GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
13. NORTH AMERICAN GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
14. NORTH AMERICAN GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
15. EUROPEAN GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
16. EUROPEAN GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
17. EUROPEAN GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
18. ASIA-PACIFIC GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
19. ASIA-PACIFIC GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
20. ASIA-PACIFIC GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
21. REST OF THE WORLD GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
22. REST OF THE WORLD GASTRIC CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
1. GLOBAL GASTRIC CANCER TREATMENT MARKET SHARE BY THERAPY, 2018 VS 2025 (%)
2. GLOBAL GASTRIC CANCER TREATMENT MARKET SHARE BY END-USER, 2018 VS 2025 (%)
3. GLOBAL GASTRIC CANCER TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
4. The US GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
5. CANADA GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
6. UK GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
7. FRANCE GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
8. GERMANY GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
9. ITALY GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
10. SPAIN GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
11. ROE GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
12. INDIA GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
13. CHINA GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
14. JAPAN GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
15. REST OF ASIA-PACIFIC GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
16. REST OF THE WORLD GASTRIC CANCER TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
